1.Meta analysis of the efficacy of digital psychological therapies on depressive symptoms among adolescents
YANG Xuan, YANG Dong, CAI Rui, TANG Yuping, YE Sheng, LUO Yaoyue
Chinese Journal of School Health 2026;47(4):531-537
Objective:
To systematically evaluate the therapeutic efficacy and maintenance effects of digital psychological therapies on depressive symptoms among adolescents, so as to provide a reference for clinical practice.
Methods:
Randomized controlled trial(RCT) investigating digital psychological therapies to improve depressive symptoms among adolescents were searched across databases, including PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang database, VIP database, and SinoMed, from database inception to November 20, 2025. Following literature screening, quality assessment, and data extraction, a Meta analysis was performed using Stata 18.0 software.
Results:
A total of 20 studies involving 2 042 adolescents aged 11-19 were included. The Meta analysis revealed that digital psychological therapies significantly alleviated depressive symptoms in adolescents ( SMD =-0.59, 95% CI =-0.85 to -0.32, P <0.01). The therapeutic effect was sustained at long term follow up ( SMD =-0.21, 95% CI =-0.34 to -0.09, P <0.01). Furthermore, depression scores in the intervention group showed a continued decrease from post intervention to long term follow up ( SMD =-0.28, 95% CI =-0.41 to -0.14, P <0.01). Egger s linear regression test indicated possible publication bias (Kendall s tall=0.28, P <0.01).
Conclusions
Digital psychological therapies can effectively improve depressive symptoms among adolescents, with stable long term efficacy. However, current evidence remains limited and exhibits substantial heterogeneity. Therefore, further large sample, high quality RCTs are warranted to validate the effectiveness of this intervention.
2.Patients' Knowledge, Attitudes, and Practices Regarding Non-pharmacologicalTreatments for Irritable Bowel Syndrome
Chengwen LI ; Qiong LIU ; Jianan CAO ; Xuan XU ; Haolong HE ; Yingchun HUANG ; Xinye LIU ; Rong LUO ; Xiaorong CHANG ; Mi LIU
Journal of Neurogastroenterology and Motility 2026;32(2):276-289
Background/Aims:
Non-pharmacological treatments are crucial for managing irritable bowel syndrome (IBS), yet patient engagement remains a challenge. Understanding patients' knowledge, attitudes, and practices regarding these treatments is essential for improving care.
Methods:
A cross-sectional study was conducted across 5 hospitals, from October 2023 to February 2024. A self-designed knowledge, attitudes, and practices questionnaire along with the IBS quality of life and IBS severity scoring system was administered, and 496 valid responses were analyzed. Statistical analyses included correlation tests, multivariate linear regression, and mediation effect analysis.
Results:
The median scores for knowledge, attitude, and practice were 28, 25.5, and 21, respectively. Significant positive correlations were found between knowledge-attitude (r = 0.195), knowledge-practice (r = 0.364), and attitude-practice (r = 0.151). The multivariate linear regression analysis further indicated that knowledge (β = 0.399, P < 0.001) and attitude (β = 0.219, P = 0.022) positively correlated with the practical performance. SEM revealed that knowledge had a significant direct effect on both attitude (β = 0.186, P = 0.013) and practice (β = 0.356, P = 0.006). However, the direct effect of attitude on practice was not significant, and attitude did not mediate the relationship between knowledge and practice.
Conclusions
IBS patients exhibit a significant gap between their positive attitudes and their actual practices concerning non-pharmacological treatments. Knowledge is a direct driver of practice, but positive attitudes alone are insufficient to translate into behavior. Healthcare providers must move beyond simply fostering positive attitudes and focus on targeted educational interventions that provide actionable knowledge and skills to improve patient outcomes.
3.Role and mechanism of semaphorins in liver diseases
Manwula MUBARESI ; Xuan DING ; Yidan LUO ; Qingshuai LIANG ; Xu ZHOU ; Yuwu LIU
Journal of Clinical Hepatology 2026;42(6):1454-1461
The liver is a vital metabolic organ sustaining human life activities, and its dysfunction is closely associated with various liver diseases. In recent years, an increasing number of studies have shown that semaphorins (SEMA) play a significant role in pathological processes such as immune inflammatory response, tumor progression, and fibrosis in liver diseases by interacting with their receptors plexins and neuropilins. This article reviews the expression, functions, and molecular mechanisms of different SEMA in viral hepatitis, hepatocellular carcinoma, liver fibrosis, nonalcoholic fatty liver disease, and hepatic ischemia-reperfusion injury, and it also explores the potential application value of SEMA in the diagnosis and treatment of liver diseases, in order to provide new ideas for precise diagnosis and targeted treatment of liver diseases.
4.Hemophagocytic syndrome secondary to visceral leishmaniasis: a case report
Chinese Journal of Schistosomiasis Control 2026;38(3):330-332
This article presents the diagnosis and treatment of a case with hemophagocytic syndrome secondary to visceral leishmaniasis. The patient had been misdiagnosed for a long period of time, and was finally definitively diagnosed as hemophagocytic syndrome secondary to visceral leishmaniasis through laboratory tests, bone marrow smear microscopy, and metagenomics next-generation sequencing. Due to unsatisfactory therapeutic efficacy, the patient's family members decided to abandon treatment, and the patient subsequently died following discharge from hospital.
5.Inflammation-driven Epithelial Remodeling and Persistent Cell-death Signaling Provide New Clues to Inflammatory Bowel Disease Relapse——a Commentary on Pang et al.’s Paper in Science (2026)
Xuan DONG ; Jia-Qi ZHANG ; Lian-Xiang LUO
Progress in Biochemistry and Biophysics 2026;53(10):2733-2738
Inflammatory bowel disease (IBD) is a chronic disorder characterized by recurrent mucosal inflammation. Although biologics and small-molecule therapies can effectively suppress inflammation, only 13%-34% of patients achieve deep histological remission, and most experience relapse within 2-3 years. Existing biomarkers, including C-reactive protein (CRP), fecal calprotectin, and endoscopic measures, have limited ability to detect subclinical molecular abnormalities, suggesting that disease-driving factors may persist even during clinical remission. Recently, Pang et al. reported a study in Science that investigated the role of epithelial cell-death signaling using a prospective adult IBD cohort comprising 80 participants and more than 900 biopsy specimens. By integrating bulk and spatial transcriptomics, patient-derived organoids, and 24-36 months of longitudinal follow-up, the authors characterized epithelial cell-death programs associated with IBD persistence. They found that the necroptosis-associated marker pRIPK3 could be detected in the absence of overt histological inflammation and persisted during advanced therapy. IFN‑γ and TNF reshaped the transcriptional landscape of specific colonic epithelial cells, inducing an inflammatory macrophage-like program termed cluster B and triggering RIPK1-independent RIPK3 signaling. This was followed by NOS2/iNOS-mediated mitochondrial apoptosis driving colonocyte death, whereas PUMA-dependent apoptosis contributed to intestinal stem-cell loss. Higher baseline pRIPK3 levels were associated with subsequent disease activity, although their independent predictive value remains to be established. These findings suggest that persistent IBD may reflect not only residual immune inflammation but also inflammation-induced pathological epithelial states. Future therapeutic strategies may therefore need to extend beyond inflammation control toward “molecular repair”, including targeting noncanonical RIPK3 signaling, modulating iNOS/PUMA-dependent mitochondrial apoptosis, and developing relapse-risk stratification strategies based on tissue biomarkers such as pRIPK3. Such approaches may help shift the therapeutic goal from “clinical remission” toward “molecular healing”.
6.Inhibition effect of secondary metabolites of Pseudomonas aeruginosa on Candida albicans and machanisms explore in vitro
Peng WANG ; Yuhang LUO ; Ping QIU ; Qi LI ; Jiawei LIU ; Linjuan CHEN ; Xuan CHEN ; Weihong WEN ; Lingqing XU
International Journal of Laboratory Medicine 2025;46(17):2097-2104
Objective To study the inhibitory effect of secondary metabolites of Pseudomonas aeruginosa(PA)on Candida albicans(CA)and to explore some of the mechanisms.Methods PA and CA strains were i-solated from clinical specimens from the hospital.Then,PA strains with inhibitory effects on CA were screened through cross-line test and co-incubation test,and crude extracts of PA secondary metabolites were prepared,and were tested together with pyocyanin,phenazine-1-carboxylic acid,1-hydroxyphenazine,and 3-ox-ododecyl-l-homoserine lactone(3-oxo-HSL).The inhibitory effects of various PA secondary metabolites on CA were determined through minimum inhibitory concentration test,minimum bactericidal concentration test,time-sterilization curve measurement,and XTT method activity measurement test,and some mechanisms by which PA secondary metabolites inhibited CA were explored.Results The strongest inhibitory effect on CA was 1-hydroxyphenazine,and at a concentration of 6.250 μg/mL,the relative activity of CA decreased to 0.00%.Next were pyocyanin and PA crude extract,and the relative fungal activity of CA decreased to 0.00%at concentrations of 200 and 100 μg/mL.1-hydroxyphenazine,pyocyanin,3-oxo-HSL and PA crude extract all had inhibitory effects on the formation of CA hyphae.Reactive oxygen species(ROS)were generated in CA cells treated with 1-hydroxyphenazine,phenazine 1-carboxylic acid,pyocyanin,and PA crude extract,and the highest levels of ROS were induced by pyocyanin and 1-hydroxyphenazine.Conclusion Phenazine secondary metabolites 1-hydroxyphenazine and pyocyanin have significant inhibitory effects on the growth and activity of CA,and both induce the highest amount of ROS.The quorum-sensing signal molecule 3-oxo-HSL have no in-hibitory effect on CA growth,but have a significant inhibitory effect on the formation of fungal hyphae.
7.Advances in the use of human respiratory stem cells in the treatment of respiratory tract infections
Xuan LIU ; Wenyan TIAN ; Ze CHEN ; Yingli QU ; Jin CAO ; Chenxi ZHANG ; Qi WEN ; Qin LUO ; Qiangqiang SHI ; Lifeng ZHANG ; Guoyong MEI ; Haijun DU ; Zhiqiang XIA ; Jun HAN
Chinese Journal of Experimental and Clinical Virology 2025;39(1):128-132
Human Respiratory Stem Cells (RSCs) play a crucial role in the maintenance, repair and regeneration of the respiratory system. As a novel therapeutic method, stem cell therapy is a popular research direction in the medical field. And with the in-depth research on the mechanism of pneumonia caused by respiratory infections in recent years, the use of RSCs to explore pneumonia caused by respiratory infections and its therapeutic strategies has become a hot topic. In this paper, we firstly outlined the types of RSCs, summarized the mechanism of pneumonia caused by respiratory tract infections, discussed the advantages of RSCs application and the progress of culture differentiation, and elaborated the therapeutic exploration of RSCs in pneumonia caused by respiratory tract infections.
8.Comparison of neuroprotective effects of hUC-MSCs-Exos on hypoxic-ischemic brain injury in neonatal mice by different administration modes
Xiao-Xia HU ; Yi-Pa SAI ; Xing-Xing CHEN ; Wei-Jing CUI ; San-Ping WANG ; Xuan LUO ; Shi-Li WU
Medical Journal of Chinese People's Liberation Army 2025;50(2):207-213
Objective To investigate the comparative neuroprotective effects of human umbilical cord mesenchymal stem cells(hUC-MSCs-Exos)administered via different routes on hypoxic ischemic brain damage(HIBD)in neonatal mice.Methods Healthy one-week-old SPF-grade BALB/c mice were randomly divided into 4 groups:sham operation group(n=6),model group(n=6),exosome group 1(n=8),exosome group 2(n=8).HIBD was induced using the Rice-Vannucci method.Exosome group 1 and Exosome group 2 were intraperitoneal injection/intranasal drip of phosphate buffer(PBS)100 μl containing 10 μl exosomes within 24 h after successful modeling,respectively.Sham operation and model groups were intraperitoneal injection of PBS 100 μl.On the 7th day after the intervention,neuromotor function was assessed using the horizontal grid test and pole climbing test.On the 2nd day after the evaluation,all mice were killed and their brains were removed by decapitation.HE staining was used to observe the pathological injury of brain tissue,toluidine blue staining was used to observe the survival of neurons in cerebral cortex,and TUNEL staining was used to observe the apoptosis of cerebral cortex cells.Results Compared with sham operation group,model group,exosome group 1 and exosome group 2 exhibited increased hind limb drops in horizontal grid test and climbing scores(P<0.05).No significant difference was found in model group,exosome group 1 and exosome group 2 in these measures(P<0.05).Significant pathology was observed in model group,exosome group 1 and exosome group 2 compared to sham operation group(P<0.05),with significantly reduced damage in exosome group 1 and exosome group 2 compared to model group(P<0.05).Compared with sham operation group,Nissl body count was lower in model group and exosome group 1 and exosome group 2,with a higher count in exosome group 2 compared to exosome group 1(P<0.05).Compared with sham operation group,apoptotic cells were higher in model group and exosome group 1 and exosome group 2,with a significant reduction in exosome group 1 and exosome group 2 compared to model group,and the lowest in exosome group 2(P<0.05).Conclusions hUC-MSCs-Exos can improve the neuronal motor function,promote neuron repair and inhibit apoptosis in HIBD mice.Intranasal administration of hUC-MSCs-Exos is more effective than intraperitoneal administration for reducing neuronal apoptosis in HIBP neonatal mice,offering a convenient and rapid method suitable for clinical application.
9.Augmentation of PRDX1-DOK3 interaction alleviates rheumatoid arthritis progression by suppressing plasma cell differentiation.
Wenzhen DANG ; Xiaomin WANG ; Huaying LI ; Yixuan XU ; Xinyu LI ; Siqi HUANG ; Hongru TAO ; Xiao LI ; Yulin YANG ; Lijiang XUAN ; Weilie XIAO ; Dean GUO ; Hao ZHANG ; Qiong WU ; Jie ZHENG ; Xiaoyan SHEN ; Kaixian CHEN ; Heng XU ; Yuanyuan ZHANG ; Cheng LUO
Acta Pharmaceutica Sinica B 2025;15(8):3997-4013
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and joint damage, accompanied by the accumulation of plasma cells, which contributes to its pathogenesis. Understanding the genetic alterations occurring during plasma cell differentiation in RA can deepen our comprehension of its pathogenesis and guide the development of targeted therapeutic interventions. Here, our study elucidates the intricate molecular mechanisms underlying plasma cell differentiation by demonstrating that PRDX1 interacts with DOK3 and modulates its degradation by the autophagy-lysosome pathway. This interaction results in the inhibition of plasma cell differentiation, thereby alleviating the progression of collagen-induced arthritis. Additionally, our investigation identifies Salvianolic acid B (SAB) as a potent small molecular glue-like compound that enhances the interaction between PRDX1 and DOK3, consequently impeding the progression of collagen-induced arthritis by inhibiting plasma cell differentiation. Collectively, these findings underscore the therapeutic potential of developing chemical stabilizers for the PRDX1-DOK3 complex in suppressing plasma cell differentiation for RA treatment and establish a theoretical basis for targeting PRDX1-protein interactions as specific therapeutic targets in various diseases.


Result Analysis
Print
Save
E-mail